VDH VIRGINIA DEPARTMENT OF HEALTH
Protecting You and Your Environment

December 17, 2021

VDH COVID-19 Monoclonal Antibody (mAb) and Therapeutics Bi-Weekly Update

Total Allocations to Monoclonal Antibody Administration Sites (September 27th- December 14th):

Monoclonal antibody	Central	Eastern	Northern	Northwest	Southwest	Total
BAM with ETE	694	400	283	710	923	**3010**
ETE Solo	370	204	470	380	1251	**2675**
Regen – COV	2841	1905	2358	4293	5091	**16488**
Sotrovimab	0	12	0	0	6	**18**
Total	**3905**	**2521**	**3111**	**5383**	**7271**	**22191**

Map of All Virginia Monoclonal Antibody Administration Sites by Region:



Clarification on the Use of REGEN-COV (casirivimab with imdevimab)

- **Clarification: Either formulation of REGEN-COV may be used to prepare intravenous (IV) or subcutaneous doses for administration**
- Please see the Regeneron website here for more information

Newly Granted FDA EUA for Evusheld:

- On 12/8/2021, FDA issued an Emergency Use Authorization (EUA) for the new drug Evusheld (Tixagevimab co-packaged with Cilgavimab) from AstraZeneca.
- Evusheld is the first product authorized for Pre-exposure Prophylaxis (Pre-EP) against COVID-19
    - This product is NOT approved for the treatment of COVID-19 or for postexposure prophylaxis (PEP) against COVID-19
- Please find an FDA News Release about Evusheld and the EUA package insert

Updated EUA for Bamlanivimab and Etesevimab for Pediatric Patients

- The FDA has expanded the EUA for the use of Bam/Ete to all age groups, notably adding all children including newborns. This applies to the use of Bam/Ete for both treatment of COVID-19 and PEP.
- Please note the FDA's updated EUA package insert

Upcoming Monoclonal Antibody Webinar details

- Please find the links to register for our VDH mAb webinars:

- 12/21/2021 from 12-1PM: https://bit.ly/31dFdm1
- 01/05/2022 from 12-1PM: https://bit.ly/3F1PXD2
- 01/13/2022 from 12-1PM: https://bit.ly/33FqilT
- 01/18/2022 from 12-1PM: https://bit.ly/3F57zxE
- 01/26/2022 from 12-1PM: https://bit.ly/3dW2v2X